PubmedID,Title,Publication Date,Non-academic Author(s),Company Affiliation(s),Corresponding Author Email
40714994,Anti-Tumor Activity of Paclitaxel-Containing Regimens in Recurrent/Refractory Wilms Tumor.,2025-Jul-25,James I Geller,"Division of Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.",
40714515,"Effectiveness of post-trastuzumab deruxtecan treatments and incidence of interstitial lung disease in HER2-positive metastatic breast cancer: a real-world, observational cohort study.",2025-Jul-25,Y Hirakawa; K Kuge; A Tanabe,"Daiichi Sankyo Co., Ltd., Tokyo, Japan.; Daiichi Sankyo Co., Ltd., Tokyo, Japan.; Daiichi Sankyo Co., Ltd., Tokyo, Japan.",kazuki.nozawa7@gmail.com.
40714206,ErbB/HER family in cancer immunology: therapeutic advances and mechanisms.,2025-Jul-24,Yuhua Shang,"Anhui Genebiol Biotech. Ltd, Hefei 230000, China.",lswsq163@163.com.
40713827,Iparomlimab and tuvonralimab (QL1706) plus chemotherapy and bevacizumab for EGFR-mutant patients with advanced non-small cell lung cancer after failure of EGFR-tyrosine kinase inhibitors: updated results from cohort 5 in the DUBHE-L-201 study.,2025-Jul-26,Hui Li; Xiaoyan Kang,"Clinical Research and Development Center, Qilu Pharmaceutical Co., Ltd, Jinan, 250131, P. R. China.; Clinical Research and Development Center, Qilu Pharmaceutical Co., Ltd, Jinan, 250131, P. R. China.",zhangli@sysucc.org.cn.
40713788,Early prediction of parotid glands secretory function based on ADC variations during radiotherapy for nasopharyngeal carcinoma: a phase II prospective study.,2025-Jul-25,Qichao Zhou,"Manteia Technologies Co., Ltd, Xiamen, China.",Freda_fm@126.com.
40713644,Safety findings from the phase 1/2 MOSAIC study of miransertib for patients with PIK3CA-related overgrowth spectrum or Proteus syndrome.,2025-Jul-25,Mo Huang; Gregory Goldmacher; Danny Liaw,"Merck & Co., Inc., Rahway, NJ, USA.; Merck & Co., Inc., Rahway, NJ, USA.; Merck & Co., Inc., Rahway, NJ, USA.",Whitney.Eng@seattlechildrens.org.
40713551,Comparison of outcomes with elranatamab and real world treatments in the UK for triple class exposed relapsed and refractory multiple myeloma.,2025-Jul-25,Carmen Tsang; Charles Duffield; Thomas Price; Sam Wood,"Pfizer Ltd, Tadworth, Surrey, UK. carmen.tsang@pfizer.com.; Pfizer Ltd, Tadworth, Surrey, UK.; Pfizer Ltd, Tadworth, Surrey, UK.; Pfizer Ltd, Tadworth, Surrey, UK.",carmen.tsang@pfizer.com.
